AstraZeneca PLC (AZN)vsIndivior PLC Ordinary Shares (INDV)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
INDV
Indivior PLC Ordinary Shares
$35.43
+5.10%
HEALTHCARE · Cap: $4.45B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4585% more annual revenue ($60.44B vs $1.29B). INDV leads profitability with a 19.5% profit margin vs 17.2%. INDV trades at a lower P/E of 19.3x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
INDV
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for INDV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Strong operational efficiency at 46.1%
Earnings expanding 82.0% YoY
Conservative balance sheet, low leverage
19.2% revenue growth
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Debt/Equity. Profitability is solid with margins at 19.5% and operating margin at 46.1%. Revenue growth of 19.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : INDV
The primary concerns for INDV are Free Cash Flow, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while INDV is a growth play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.17 — expect wider price swings.
INDV is growing revenue faster at 19.2% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 62/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?